美国食品药品监督管理局（FDA）已批准Gedatolisib与氟维司群联合治疗方案，可选择性地加用哌柏西利，用于治疗激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌患者。这一批准为这类特定亚型的乳腺癌患者提供了新的治疗选择。
美国食品药品监督管理局（FDA）已批准Gedatolisib与氟维司群联合治疗方案，可选择性地加用哌柏西利，用于治疗激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌患者。这一批准为这类特定亚型的乳腺癌患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.